Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 147 | 1 | 154 | +8 |
| Shares | 51.4M | 12.5K | 54.5M | +3.18M (+6.2%) |
| Value | $1.51B | $367.0K | $1.18B | −$330.2M (−21.9%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (29)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (21)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| OrbiMed Advisors LLC | 813,500 | $23.9M |
| Avoro Capital Advisors LLC | 473,100 | $13.9M |
| Maven Securities LTD | 100,000 | $2.93M |
| SEI Investments Co | 69,665 | $2.04M |
| Dynamic Technology Lab Private Ltd | 30,857 | $906.0K |
| Seven Eight Capital, LP | 30,053 | $881.8K |
| Pentwater Capital Management LP | 30,000 | $880.2K |
| XTX Topco Ltd | 14,751 | $432.8K |
| STRS Ohio | 12,300 | $360.0K |
| Axq Capital, LP | 10,600 | $311.0K |
| Capstone Investment Advisors, LLC | 10,150 | $297.8K |
| Ikarian Capital, LLC | 10,000 | $293.4K |
| Boulder Hill Capital Management LP | 9,400 | $275.8K |
| Artia Global Partners LP | 8,339 | $244.7K |
| Quantbot Technologies LP | 4,859 | $142.6K |
| Values First Advisors, Inc. | 1,733 | $50.9K |
| Advisory Services Network, LLC | 500 | $14.7K |
| TCI Wealth Advisors, Inc. | 142 | $4.17K |
| The PNC Financial Services Group, Inc. | 100 | $2.93K |
| Ellevest, Inc. | 32 | $939 |
| US Bancorp | 18 | $528 |
Not filed for Q2 2023 yet (1)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Kula Investments, LLC | 12,507 | $367.0K |